Drug Trial Radar · NCT02013154
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
May 5, 2014
Primary completion
Jul 19, 2019
Study completion Jan 11, 2021
Sponsor
- Lead sponsor
- Leap Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
Conditions
- Esophageal Neoplasms
- Adenocarcinoma of the Gastroesophageal Junction
- Gastroesophageal Cancer
- Squamous Cell Carcinoma
- Gastric Adenocarcinoma
Interventions
DKN-01 150 mgDrug
Administered by IV infusion
PaclitaxelDrug
Administered by IV infusion
PembrolizumabDrug
Administered by IV infusion
DKN-01 300 mgDrug
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with dose limiting toxicities in each treatment armTime frame: Baseline to End of Cycle 1 (each cycle is 28 days, except each cycle is 21 days when DKN-01 is administered with pembrolizumab)
- Number of subjects with treatment emergent adverse events related to study treatment (DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab)Time frame: Baseline until 30 days after last dose of study drug
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cedars Sinai Medical Care Foundation
Los Angeles, California
Smilow Cancer Hospital at Yale - New Haven
New Haven, Connecticut
Northwestern University
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Duke University
Durham, North Carolina
Tennessee Oncology / Sarah Cannon Research Institute
Nashville, Tennessee
Vanderbilt University / VICC
Nashville, Tennessee
Mary Crowley Cancer Center
Dallas, Texas
CTRC @ The University of Texas Health Science Center at San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.